Latest Healthcare News

BCAL Diagnostics has secured national ethics approval to establish a large-scale registry tracking the clinical impact of its BREASTESTplus blood test for breast cancer diagnosis, aiming to enhance doctor adoption and reimbursement prospects.

Biotron Limited has completed a $1 million placement to fund the development of its newly acquired Sedarex Limited assets, marking a strategic expansion of its antiviral portfolio.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Vitasora Health has secured AU$3.56 million from a cornerstone investor, issuing over 118 million shares, while confirming compliance with key regulatory disclosure obligations.

Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

Healius Limited has landed a significant five-year contract to provide pathology services to the Australian Defence Force, leveraging its national network and digital health solutions.

Paragon Care Limited is set to acquire Indonesian medical aesthetics leader Haju Medical for A$70 million, aiming to boost its footprint across Asia Pacific and accelerate growth in the aesthetics sector.

Pro Medicus Limited’s U.S. subsidiary has landed a $25 million, seven-year contract to deploy its cloud-based Visage 7 Open Archive with BayCare, extending an existing partnership and marking a significant step in its North American growth.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

BTC Health has broadened its medical product portfolio through strategic acquisitions and organic growth, reporting strong early revenue gains while cautiously navigating the uncertain timing of ECMO system adoption.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.